Primary medication nonadherence is a widespread public health problem; however, the subject lacks standardized definitions and measures.
Primary medication nonadherence is a widespread public health problem; however, the subject lacks standardized definitions and measures making it difficult to establish the true extent of the problem and track changes over time.
In a study published in Journal of Managed Care and Specialty Pharmacy (JMCP) Alex Adams, PharmD, MPH, and Samuel Stolpe, PharmD, compiled set parameters for a new industry measure.
Study Objectives
Primary and secondary nonadherence are distinct subsets of medication non-adherence.
Since most medication adherence research to date has focused on secondary non-adherence, PMN has been identified as a major research gap. There are lack of standardized measures and limited understanding of its true extent. Adams and Stolpe have tried to establish more standardized PMN measures so that it might be helpful in benchmarking and quality improvement initiatives.
For the study, a literature review was conducted using Google Scholar and PubMed databases, covering the time period from 1990 to June 2015. Search terms included “primary non-adherence,” “primary medication non-adherence,” “medication non-redemption,” “medication non-fulfillment,” “primary non-compliance,” “first-fill prescriptions,” and “newly initiated drug therapy.”
Clarity on Terminology
The most frequently used terms (in 77% of all studies) to describe PMN were “primary medication nonadherence” or “primary adherence.” Three studies used the term “prescription abandonment” for the same. But PMN is not the same as prescription abandonment. “Prescription abandonment” is traditionally used in studies as a broader term than PMN and occurs whenever a prescription is filled by a pharmacy but not claimed by the patient.
“PMN occurs when a new medication is prescribed for a patient, but the patient does not obtain the medication, or appropriate alternative, within an acceptable period of time after it was prescribed,” the authors wrote.
Standardization Leads to Effectiveness
Poor medication adherence is an increasing public health issue that has been linked to worse health outcomes, increased hospitalizations, and increased health care costs. Medication nonadherence is responsible for a cost of $290 billion annually in the United States.
It is very important to develop a consensus-based definition and quality measure of PMN. Doing that would enable one step closer towards consistent measurement of this phenomenon. Especially since e-prescribing is becoming the leading mode of prescription transmission, it is important to have standardized methods of tracking PMN in order to study the effectiveness of interventions to reduce PMN.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More